This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Ranganathan S , Salazar H , Benetatos CA , Hudes GR
Immunohistochemical analysis of beta-tubulin isotypes in human prostate carcinoma and benign prostatic hypertrophy
Prostate. 1997 Mar 1;30(4) :263-268
AbstractBACKGROUND. beta-tubulin, the intracellular target of several antimicrotubule agents, is encoded by at least six genes and exists as multiple isotypes with tissue-specific expression. Previous in vitro studies indicated that tubulin isotype composition may affect polymerization properties, dynamics, and sensitivity to drugs. METHODS. To investigate the isotype composition of beta-tubulin in human prostate, tissues were collected from 26 patients after radical prostatectomy and sections were stained with isotype-specific antibodies. RESULTS. beta(IV) tubulin is the predominant isotype in benign prostatic hyperplasia (BPH) and adenocarcinoma, showing significantly stronger immunohistochemical expression than beta(II) and beta(III), particularly in Gleason's grade 3 and 4 cancers. Staining for the beta(II) isotype was invariably weak and often absent in BPH and normal glands. There was a marked increase in beta(II) isotype stain from BPH to cancer in 77% of the patients, suggesting that the expression of this isotype is related to malignant status. CONCLUSIONS. The beta(II) tubulin isotype is a potential marker for prostate adenocarcinoma. The possibility that tumor beta-tubulin isotype composition may effect the response to antimicrotubule drug therapy in prostate cancer and other tumors merit investigation. (C) 1997 Wiley- Liss, Inc.
NotesTimes Cited: 7 English Article WQ448 PROSTATE